Eli Lilly and Company reported strong financial results for the second quarter of 2025, with revenue reaching $15.56 billion, a 38% increase year-over-year, surpassing analyst estimates of approximately $14.7 billion. Adjusted earnings per share (EPS) rose 61% year-over-year to $6.31, beating consensus estimates near $5.59. Key product sales included Mounjaro, which generated $5.20 billion in revenue, up 68% year-over-year, and Zepbound, which posted $3.38 billion in revenue, a 172% increase year-over-year and exceeding estimates of $3.07 billion. Verzenio also contributed $1.49 billion in revenue, up 12% year-over-year. Net income for the quarter was $5.66 billion, reflecting a 91% increase from the previous year. Eli Lilly raised its full-year 2025 guidance, projecting revenue between $60 billion and $62 billion, up from a prior range of $58 billion to $61 billion. The company also increased its adjusted EPS forecast to a range of $21.75 to $23.00, compared to the previous guidance of $20.78 to $22.28. The upward revisions were attributed to strong business performance and favorable foreign exchange rates. Additionally, Eli Lilly noted positive developments in its oncology and cardiometabolic health pipelines. The estimated tax rate was increased due to new U.S. tax legislation.